Effectiveness of 17-α-Hydroxyprogesterone Caproate on Preterm Birth Prevention in Women with History-Indicated Cerclage

Abstract

Objective To determine whether 17-α-hydroxyprogesterone caproate (17P) reduces the incidence of preterm birth in women with a history-indicated cerclage.

Study Design Retrospective cohort study of women who received a cerclage for a prior preterm birth, analyzed based on exposure to 17P. The primary outcome variable was delivery < 35 weeks. Secondary outcomes were preterm birth < 37, 32, 28, and 24 weeks; interval between cerclage placement and delivery; gestational age at delivery; and infant birth weight.

Results Fourteen women received 17P and 80 did not. Baseline characteristics did not differ between these two groups. Preterm delivery at < 35 weeks did not differ between those who received 17P and those who did not (29% versus 15%, p = 0.46). There were no significant differences between the groups for any other outcome.

Conclusion 17P does not appear to have an effect on preterm birth < 35 weeks in women with a history-indicated cerclage.

Keywords

cerclage - progesterone - preterm birth prevention - history-indicated cerclage

Notes

Presented as an abstract at the 30th Annual Society for Maternal-Fetal Medicine Meeting: The Pregnancy Meeting in Chicago, Illinois, February 2010. Mackeen D, Rafael T, Zavodnick J, Berghella V. Effectiveness of 17P on prevention of PTB in women with a history-indicated cerclage. Am J Obstet Gynecol 2010;201(6S):S193.

• References

• 1 Hamilton BE, Martin JA, Ventura SJ. Births: Preliminary data for 2007. National vital statistics reports, Web release; vol 57 no 12. Hyattsville, MD: National Center for Health Statistics; 2009
• 2 Martin JA, Hamilton BE, Sutton PD, Ventura SJ , et al. Births: Final data for 2006. National vital statistics reports; vol 57 no 7. Hyattsville, MD: National Center for Health Statistics; 2009
• 3 Anderson RN, Smith BL. Deaths: leading causes for 2001. Natl Vital Stat Rep 2003; 52: 1-85
• 4 Berghella V, Seibel-Seamon J. Contemporary use of cervical cerclage. Clin Obstet Gynecol 2007; 50: 468-477
• 5 Fox NS, Chervenak FA. Cervical cerclage: a review of the evidence. Obstet Gynecol Surv 2008; 63: 58-65
• 6 Osterman MJK, Martin JA, Menacker F. Expanded health data from the new birth certificate, 2006. Natl Vital Stat Rep 2009; 58: 1-24
• 7 Meis PJ, Klebanoff M, Thom E , et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348: 2379-2385
• 8 Spong CY, Meis PJ, Thom EA , et al; National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. Am J Obstet Gynecol 2005; 193 (3 Pt 2) 1127-1131
• 9 Society for Maternal Fetal Medicine Publications Committee. ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth. Obstet Gynecol 2008; 112: 963-965
• 10 Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A. Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007; 196: e1-e4 ; discussion 421
• 11 Berghella V, Figueroa D, Szychowski JM , et al; Vaginal Ultrasound Trial Consortium. 17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Am J Obstet Gynecol 2010; 202: e1-e6
• 12 Szychowski JM, Berghella V, Owen J , et al; for the Vaginal Ultrasound Trial Consortium. Cerclage for the prevention of preterm birth in high risk women receiving intramuscular 17-α-hydroxyprogesterone caproate. J Matern Fetal Neonatal Med 2012; (Epub ahead of print)
• 13 Owen J, Hankins G, Iams JD , et al. Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length. Am J Obstet Gynecol 2009; 201: e1-e8
• 14 MRC/RCOG Working Party on Cervical Cerclage. Macnaughton MC, Chalmers IG, Dubowitz V, Dunn PM, Grant AM, McPherson K, Pearson JF, Peto R, Turnbull AC. Final report of the Medical Research Council/Royal College of Obstetricians and Gynaecologists Multicentre Randomised Trial of Cervical Cerclage. BJOG: An International Journal of Obstetrics & Gynaecology 1993; 100: 516-523 . DOI: 10.1111/j.1471-0528.1993.tb15300.x.
• 15 Rebarber A, Cleary-Goldman J, Istwan NB , et al. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage. Am J Perinatol 2008; 25: 271-275
• 16 American College of Obstericians and Gynecologists. ACOG Practice Bulletin. Cervical insufficiency. Obstet Gynecol 2003; 102 (5 Pt 1) 1091-1099
• 17 Fox NS, Gelber SE, Kalish RB, Chasen ST. History-indicated cerclage: practice patterns of maternal-fetal medicine specialists in the USA. J Perinat Med 2008; 36: 513-517
• 18 Berghella V, Odibo AO, To MS, Rust OA, Althuisius SM. Cerclage for short cervix on ultrasonography: meta-analysis of trials using individual patient-level data. Obstet Gynecol 2005; 106: 181-189